Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up

Knyazev, Oleg V.; Kagramanova, Anna V.; Parfenov, Asfold I.

doi:10.2478/prolas-2022-0095

Abstract

We investigated the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve “deep remission” in patients with luminal Crohn disease (CD). Our study included 72 patients (age 19–62 years) (Ме = 29) with luminal CD. Patients in the 1st group (n = 21) received standard 5-aminosalicylic acid (5-ASA) and glucocorticosteroid therapy in combination with MSC. Patients in the 2nd group (n = 32) were prescribed anti-cytokine therapy IFX. Patients in the 3rd group (n = 19) received MSC and IFX. Clinical and immunobiological (C-reactive protein-CRP and faecal calprotectin-FCP) showed a more significant decrease of local and systemic inflammation activity in the 3rd group of patients. During a 5-year follow-up we observed longer duration of remission in patients who received MSC and IFX compared to the 1st (р = 0,04) and 2nd groups of patients (р = 0.038). Combination therapy of bone marrow-derived MSC and IFL provides “deep remission” in patients with luminal CD and has higher prognostic value for duration of CD remission period.

References

Baert, F. J., D’Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., Rutgeerts, P. J. (1999). Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn’s ileocolitis. Gastroenterology, 116 (1), 22–28.10.1016/S0016-5085(99)70224-6
Search in Google Scholar Back to article
Best, W. R., Becktel, J. M., Singleton, J. W., Kern Jr., F. (1976). Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 70 (3), 439–444.10.1016/S0016-5085(76)80163-1
Search in Google Scholar Back to article
Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: Results from EXTEND. J. Crohn’s Colitis, 4, S11. Abstract OP31.
Search in Google Scholar Back to article
Colombel, J., Rutgeerts, P., Sandborn, W. J. (2010). Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn’s disease: Data from EXTEND. Gut, 59 (Suppl. 3), A80. Abstract OP371.
Search in Google Scholar Back to article
Das, M., Sundell, I. B., Koka, P. S. (2013). Adult mesenchymal stem cells and their potency in the cellbased therapy. J. Stem Cells, 8 (1), 1–16.
Search in Google Scholar Back to article
Duijvestein, M., Molendijk, I., Roelofs, H., Vos, A. C., Verhaar, A. P., Reinders, M. E., Fibbe, W. E., Verspaget, H. W., van den Brink, G. R., Wildenberg, M. E., Hommes, D. W. (2011). Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy, 13 (9), 1066–1073.10.3109/14653249.2011.59737921846292
Search in Google Scholar Back to article
Froslie, K. F., Jahnsen, J., Moum, B. A. (2007). Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology, 133 (2), 412–422.10.1053/j.gastro.2007.05.05117681162
Search in Google Scholar Back to article
Huang, H. R., Zan, H., Lin, Y., Zhong, Y. Q. (2014). Effects of azathioprine and infliximab on mesenchymal stem cells derived from the bone marrow of rats in vitro. Mol. Med. Rep., 9 (3), 1005–1012. DOI: 10.3892/mmr.2014.1905.10.3892/mmr.2014.190524435621
Search in Google Scholar Back to article
Kaplan, E. I., Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53, 457.10.1080/01621459.1958.10501452
Search in Google Scholar Back to article
Knyazev, O., Parfenov, A., Shcherbakov, P., Ruchkina, I., Konoplyanikov, A. (2013). Refractory forms of Crohn's disease cell therapy. Cell. Technol. Biol. Med., 3, 145–152.
Search in Google Scholar Back to article
Lichtenstein, G. R., Rutgeerts, P. (2010). Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis., 16, 338–346. DOI: 10.1002/ibd.20997.10.1002/ibd.2099719637362
Search in Google Scholar Back to article
Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M., Lagneaux, L. (2016). Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy, 18 (2), 160–171. DOI: 10.1016/j.jcyt.2015.10.011.10.1016/j.jcyt.2015.10.01126794710
Search in Google Scholar Back to article
Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M., Colombel, J. F. (2010). Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol., 7 (1), 15–29.10.1038/nrgastro.2009.20319949430
Search in Google Scholar Back to article
Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I., Pavlov, V. V. (2004). Preparation and use in medicine, cell cultures of human mesenchymal stem cells of bone marrow cells. Herald of the Russian Academy of Medical Sciences, 59 (9), 71–76.
Search in Google Scholar Back to article
Vorobyev, G. I., Khalif, I. L. (2008). Non-specific Inflammatory Bowel Disease. Miklos.
Search in Google Scholar Back to article
Watkins, P. E., Warren, B. F., Stephens, S., Ward, P., Foulkes, R. (1997). Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut, 40 (5), 628–633.10.1136/gut.40.5.62810271669203942
Search in Google Scholar Back to article
Zallot, C., Peyrin-Biroulet, L. (2013). Deep remission in inflammatory bowel disease: Looking beyond symptoms. Curr. Gastroenterol. Rep., 15 (3), 315. DOI: 10.1007/s11894-013-0315-7.10.1007/s11894-013-0315-723354742
Search in Google Scholar Back to article

Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up

Abstract

Paradigm

My account